Preliminary 1H21 sales (8.5ML) and EBITDA ($7.1M) provide the first strong evidence of the success of prior investment in plant and people. A growing sales and marketing team has been able to take an increasingly efficient production of a broader product range and get it onto shelves and into venues. These results demonstrate the positive impact on margin, and our valuation of $0.112 (prior $0.080) reflects our earnings upgrades.
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.